Business
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
(TheNewswire) LONDON, ONTARIO - TheNewswire - April 6...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n LONDON, ONTARIO -\n \n \n TheNewswire -\n \n \n April 6, 2021 - Sernova Corp. (TSXV:SVA)\n(OTC:SEOVF) (FSE/XETRA:PSH\n \n ), a leading clinical-stage\nregenerative medicine therapeutics company, is pleased to announce\nthat lead principal investigator Dr. Piotr Witkowski and the Clinical\nTrial Investigator Team for its US Phase I/II Type 1 Diabetes clinical\ntrial will present data and observations from the ongoing study in a\nposter presentation at the upcoming American Diabetes Association’s\n(ADA) 81\n \n st\n \n Scientific\nSessions to be held June 25 - 29, 2021.\n \n \n The abstract will also be published online at the journal\n \n Diabetes®\n \n website and the\npresentation will be available to conference attendees on Friday, June\n25, 2021.\n \n \n Dr. Witkowski, Director, Pancreatic and Islet Transplant Program at\nthe University of Chicago, is also scheduled to deliver a lecture\ntitled “\n \n Islet Transplantation –\nBenefits and Shortcomings”,\n \n as part of the\n \n Clinical and Regulatory Hurdles Facing\nIslet Transplantation\n \n session on Monday, June 28, 2021, at 8:00\nam ET.\n \n \n \n Note\n \n : all information contained in the submitted\nabstract should be considered preliminary and subject to change until\nthe study data and observations are fully presented at the ADA 81st\nScientific Sessions and is subject to embargo until June 25, 2021, at\n11:30 am ET.\n \n \n \n ABOUT SERNOVA’S CELL POUCH\nSYSTEM\n \n \n \n The Cell Pouch, as part of the Cell Pouch System, is a novel,\nproprietary, scalable, implantable macro- encapsulation device\nsolution designed for the long-term survival and function of\ntherapeutic cells. The device upon implantation is designed to\nincorporate with tissue, forming highly vascularized tissue chambers\nfor the transplantation and function of therapeutic cells, which then\nrelease proteins and hormones as required to treat disease. The Cell\nPouch, along with therapeutic cells, has been shown to provide\nlong-term safety and efficacy in small and large animal models of\ndiabetes and has been proven to provide a biologically compatible\nenvironment for insulin-produc...